A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
Diabetes Mellitus, Type 2

About this trial
This is an interventional basic science trial for Diabetes Mellitus, Type 2 focused on measuring Phase 1, Multiple Ascending Doses, Safety, Pharmacokinetics, Healthy Volunteers, Type 2 Diabetic Patients
Eligibility Criteria
Inclusion Criteria:
- Healthy males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive.
- Type 2 diabetic males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of 7.0-10.0%, inclusive.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
- Additionally, type 2 diabetic patients who have history of diabetic complications with significant end-organ damage or pharmacologic treatment for diabetes in addition to metformin.
Sites / Locations
- Pfizer Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
2 mg PF-05190457 or Placebo BID
10 mg PF-05190457 or Placebo BID
40 mg PF-05190457 or Placebo BID
150 mg PF-05190457 or Placebo BID
5 mg PF-05190457 or Placebo QD
50 mg PF-05190457 or Placebo QD
xxx mg PF-05190457 or Placebo
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Dose and dose frequency may be adjusted based on emerging safety and PK data.
Dose and dose frequency to be determined based on emerging safety and PK data.